Cargando…

ColdZyme® protects airway epithelia from infection with BA.4/5

Vaccines against SARS-CoV-2 protect from critical or severe pathogenesis also against new variants of concern (VOCs) such as BA.4 and BA.5, but immediate interventions to avoid viral transmission and subsequent inflammatory reactions are needed. Here we applied the ColdZyme® medical device mouth spr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Viktoria, Zaderer, Stefanie, Dichtl, Rosa, Bellmann-Weiler, Cornelia, Lass-Flörl, Wilfried, Posch, Doris, Wilflingseder
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624019/ https://www.ncbi.nlm.nih.gov/pubmed/36316674 http://dx.doi.org/10.1186/s12931-022-02223-2

Ejemplares similares

Correction: ColdZyme® protects airway epithelia from infection with BA.4/5
por: Zaderer, Viktoria, et al.
Publicado: (2023)

ColdZyme Maintains Integrity in SARS-CoV-2-Infected Airway Epithelia
por: Posch, W., et al.
Publicado: (2021)

SARS-CoV-2–infected primary human airway epithelia illustrate mucus hypersecretion
por: Posch, Wilfried, et al.
Publicado: (2021)

Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections
por: Dichtl, Stefanie, et al.
Publicado: (2022)

Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5
por: Diem, Gabriel, et al.
Publicado: (2023)

C5aR inhibition of nonimmune cells suppresses inflammation and maintains epithelial integrity in SARS-CoV-2–infected primary human airway epithelia
por: Posch, Wilfried, et al.
Publicado: (2021)

Salivary antibodies induced by BA.4/BA.5-convalescence or bivalent booster Immunoglobulin vaccination protect against novel SARS-COV-2 variants of concern
por: Diem, Gabriel, et al.
Publicado: (2023)

Serum Neutralization Against SARS-CoV-2 Variants Is Heterogenic and Depends on Vaccination Regimen
por: Jäger, Michael, et al.
Publicado: (2022)

Turning the World Upside-Down in Cellulose for Improved Culturing and Imaging of Respiratory Challenges within a Human 3D Model
por: Zaderer, Viktoria, et al.
Publicado: (2019)

GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events
por: Zaderer, Viktoria, et al.
Publicado: (2023)

Omicron subvariants illustrate reduced respiratory tissue penetration, cell damage and inflammatory responses in human airway epithelia
por: Zaderer, Viktoria, et al.
Publicado: (2023)

Dexamethasone Promotes Aspergillus fumigatus Growth in Macrophages by Triggering M2 Repolarization via Targeting PKM2
por: Luvanda, Maureen K., et al.
Publicado: (2021)

Dexamethasone Creates a Suppressive Microenvironment and Promotes Aspergillus fumigatus Invasion in a Human 3D Epithelial/Immune Respiratory Model
por: Luvanda, Maureen K., et al.
Publicado: (2021)

Immunity of Heterologously and Homologously Boosted or Convalescent Individuals Against Omicron BA.1, BA.2, and BA.4/5 Variants
por: Jäger, Michael, et al.
Publicado: (2023)

Antiviral drugs block replication of highly immune-evasive Omicron subvariants ex vivo, but fail to reduce tissue inflammation
por: Dichtl, Stefanie, et al.
Publicado: (2023)

Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern
por: Lafon, Eliott, et al.
Publicado: (2022)

Early intervention with ColdZyme mouth spray after self-diagnosis of common cold: A randomized, double-blind, placebo-controlled study
por: Lindberg, B. Fredrik, et al.
Publicado: (2023)

Evaluation of ColdZyme® Mouth Spray on prevention of upper respiratory tract infections in a boy with primary immunodeficiency: a case report
por: Clarsund, Mats, et al.
Publicado: (2016)

Role of Complement Receptors (CRs) on DCs in Anti-HIV-1 Immunity
por: Posch, Wilfried, et al.
Publicado: (2020)

Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees
por: Jäger, Michael, et al.
Publicado: (2022)

Inactivation of SARS‐CoV‐2 and HCoV‐229E in vitro by ColdZyme® a medical device mouth spray against the common cold
por: Gudmundsdottir, Ágústa, et al.
Publicado: (2020)

Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients
por: Lafon, Eliott, et al.
Publicado: (2021)

Does Trypsin Oral Spray (Viruprotect(®)/ColdZyme(®)) Protect against COVID-19 and Common Colds or Induce Mutation? Caveats in Medical Device Regulations in the European Union
por: Huijghebaert, Suzy, et al.
Publicado: (2021)

Co- but not Sequential Infection of DCs Boosts Their HIV-Specific CTL-Stimulatory Capacity
por: Schönfeld, Manuela, et al.
Publicado: (2019)

Salivary IgAs and Their Role in Mucosal Neutralization of SARS-CoV-2 Variants of Concern
por: Diem, Gabriel, et al.
Publicado: (2022)

A Laboratory-Based Study on Multiple Biomarker Testing in the Diagnosis of COVID-19-Associated Pulmonary Aspergillosis (CAPA): Real-Life Data
por: Lass-Flörl, Cornelia, et al.
Publicado: (2022)

Diagnostic Performance of a Novel Multiplex PCR Assay for Candidemia among ICU Patients
por: Fuchs, Stefan, et al.
Publicado: (2019)

Microbiological and Molecular Diagnosis of Mucormycosis: From Old to New
por: Lackner, Nina, et al.
Publicado: (2021)

P80 Natural Essence Exerts Efficient Anti-HIV-1- as Well as Adjuvant Effects in DCs
por: Zaderer, Viktoria, et al.
Publicado: (2021)

Comment on Huijghebaert et al. Does Trypsin Oral Spray (Viruprotect(®)/ColdZyme(®)) Protect against COVID-19 and Common Colds or Induce Mutation? Caveats in Medical Device Regulations in the European Union. Int. J. Environ. Res. Public Health 2021, 18, 5066
por: Davison, Glen
Publicado: (2022)

Fast-track development of an in vitro 3D lung/immune cell model to study Aspergillus infections
por: Chandorkar, P., et al.
Publicado: (2017)

Evaluation of Inoculum Preparation for Etest and EUCAST Broth Dilution to Detect Anidulafungin Polyresistance in Candida glabrata
por: Knoll, Miriam Alisa, et al.
Publicado: (2022)

β-1,3-glucan-lacking Aspergillus fumigatus mediates an efficient antifungal immune response by activating complement and dendritic cells
por: Steger, Marion, et al.
Publicado: (2018)

Wie sich COVID-19 in der 3D-Zellkultur simulieren lässt
por: Wilflingseder, Doris, et al.
Publicado: (2022)

Complement Potentiates Immune Sensing of HIV-1 and Early Type I Interferon Responses
por: Posch, Wilfried, et al.
Publicado: (2021)

Reply to Davison, G. Comment on “Huijghebaert et al. Does Trypsin Oral Spray (Viruprotect(®)/ColdZyme(®)) Protect against COVID-19 and Common Colds or Induce Mutation? Caveats in Medical Device Regulations in the European Union. Int. J. Environ. Res. Public Health 2021, 18, 5066”
por: Huijghebaert, Suzy, et al.
Publicado: (2022)

HIV-1 Trans Infection via TNTs Is Impeded by Targeting C5aR
por: Bertacchi, Giulia, et al.
Publicado: (2022)

Airway Epithelia
por: Johnson, Larry G., et al.
Publicado: (2003)

Complement-Opsonized HIV-1 Overcomes Restriction in Dendritic Cells
por: Posch, Wilfried, et al.
Publicado: (2015)

Caminos vecinales con técnica perma-zyme
por: Hernández Gil, José Angel
Publicado: (1992)

Cannot write session to /tmp/vufind_sessions/sess_uui2v1tol3jh507hfhtvuh2t77